Results 31 to 40 of about 126,356 (297)

Effects of sacubitril/valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy [PDF]

, 2016
Background—In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the ...
Gong, Jianjian, Jhund, Pardeep S., Lefkowitz, Martin P., McMurray, John J.V., Okumura, Naoki, Packer, Milton, Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +11 more
core   +2 more sources

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. [PDF]

, 2019
BACKGROUND: Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to underuse of life-saving therapy.
Andersson, B, Anker, SD, Beta-Blockers in Heart Failure Collaborative Group, Böhm, M, Cleland, JGF, Coats, AJS, Damman, K, Flather, MD, Gill, SK, Holmes, J, Kjekshus, J, Kotecha, D, Manzano, L, McMurray, JJV, Packer, M, Redon, J, Rigby, AS, Rosano, G, Ruschitzka, F, van Veldhuisen, DJ, von Lueder, TG, Wedel, H, Wikstrand, J   +22 more
core   +8 more sources

Current patterns of beta‐blocker prescription in cardiac amyloidosis: an Italian nationwide survey

ESC Heart Failure, 2021
Aims The use of beta‐blocker therapy in cardiac amyloidosis (CA) is debated. We aimed at describing patterns of beta‐blocker prescription through a nationwide survey.
Giacomo Tini, Francesco Cappelli, Elena Biagini, Beatrice Musumeci, Marco Merlo, Lia Crotti, Matteo Cameli, Gianluca Di Bella, Alberto Cipriani, Francesca Marzo, Federico Guerra, Cinzia Forleo, Christian Gagliardi, Mattia Zampieri, Samuela Carigi, Pier Filippo Vianello, Giulia Elena Mandoli, Giuseppe Ciliberti, Luca Lichelli, Davide Mariani, Aldostefano Porcari, Domitilla Russo, Roberto Licordari, Alberto Ponziani, Italo Porto, Federico Perfetto, Camillo Autore, Claudio Rapezzi, Giafranco Sinagra, Marco Canepa   +29 more
doaj   +1 more source

Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling. [PDF]

, 2014
Heart failure is one of the leading causes of mortality in Western countries, and β-blockers are a cornerstone of its treatment. However, the response to these drugs is variable among individuals, which might be explained, at least in part, by genetic ...
Barrese, V, Femminella, GD, Ferrara, N, Rengo, G   +3 more
core   +2 more sources

Case of chronic indolent pheochromocytoma that caused medically controlled hypertension but treatment-resistant diabetes mellitus [PDF]

, 2017
No abstract ...
Cho, Eun Joo, Dominiczak, Anna F., Jennings, Garry L.R., Lee, Hae-Young, Lee, HyunJung   +4 more
core   +1 more source

Efficacy of beta-blocker therapy in symptomatic athletes with exercise-induced intra-ventricular gradients

Cardiovascular Ultrasound, 2010
Background Upright exercise stress echocardiography (SE) induces significant intraventricular gradient (IVG) and systolic anterior motion (SAM) in a large proportion of symptomatic athletes, who may therefore benefit from a negative inotropic therapy ...
Cotrim Carlos, Lopes Luís R, Almeida Ana R, Miranda Rita, Ana Almeida G, Cotrim Hortense, Andrade José P, Picano Eugenio, Carrageta Manuel   +8 more
doaj   +1 more source

The association between beta-blocker use and chronic obstructive pulmonary disease risk, severity, and exacerbation

Medical Journal of Babylon, 2021
Background: There is controversy about the role of beta-blockers in the number of acute exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Hemin Khalid Saber
doaj   +1 more source

Efficacy and Tolerability of Travoprost 0.004%/Timolol 0.5% Fixed-Dose Combination for the Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with Beta-Blocker Monotherapy

Journal of Ophthalmology, 2017
Objective. To evaluate the efficacy and tolerability of travoprost 0.004%/timolol 0.5% fixed-dose combination (TTFC) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) inadequately controlled on beta-blocker monotherapy. Methods.
Simon Fabian Lerner, Ki Ho Park, Douglas A. Hubatsch, Valeriy Erichev, Jose A. Paczka, Timothy V. Roberts   +5 more
doaj   +1 more source

The role of plasma concentrations and drug characteristics of beta‐blockers in fall risk of older persons

Pharmacology Research & Perspectives, 2023
Beta‐blocker usage is inconsistently associated with increased fall risk in the literature. However, due to age‐related changes and interindividual heterogeneity in pharmacokinetics and dynamics, it is difficult to predict which older adults are more at ...
K. J. Ploegmakers, E. P. vanPoelgeest, L. J. Seppala, S. C. vanDijk, L. C. P. G. M. deGroot, S. Oliai Araghi, N. M. vanSchoor, B. Stricker, K. M. A. Swart, A. G. Uitterlinden, R. A. A. Mathôt, N. van derVelde   +11 more
doaj   +1 more source

Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study [PDF]

, 2017
Background: Angiotensin converting enzyme inhibitors (ACEIs) are recommended as first-line therapy in patients with heart failure with reduced ejection fraction (HFrEF). The comparative effectiveness of different ACEIs is not known. Methods and results:
Agewall, Stefan, Atar, Dan, Clark, Andrew L., Cleland, John G.F., Corletto, Anna, Frankenstein, Lutz, Fröhlich, Hanna, Goode, Kevin, Grundtvig, Morten, Henning, Felix, Hole, Torstein, Katus, Hugo A., Kazmi, Syed, Schellberg, Dieter, Täger, Tobias   +14 more
core   +1 more source